Physician profile
Rina Jaffe
NPI 1376625202
$1,497.05
in general payments reported to CMS, 2019-2025
20 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $17.36 · 2021: $264 · 2022: $295 · 2023: $318 · 2024: $221 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $313.44 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Cranial Technologies, INC | $191.20 | 2019-2025 | Doc Band |
| Kaleo, INC. | $189.08 | 2021-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $171.81 | 2019-2025 | Bexsero |
| Pfizer INC. | $133.06 | 2019-2025 | |
| Sanofi Pasteur INC. | $111.56 | 2021-2024 | |
| Seqirus USA INC | $55.32 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Hologic Sales and Service, LLC | $50.98 | 2023-2025 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $47.59 | 2021-2024 | Vpriv |
| Sobi, INC | $31.19 | 2019-2021 | |
| Neurelis, INC. | $30.25 | 2024 | Valtoco |
| Genentech USA, INC. | $28.95 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $23.98 | 2023 | |
| Phadia US INC. | $22.60 | 2022 | |
| Galderma Laboratories, L.P. | $22.35 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.83 | 2019 | |
| Alk-Abello, INC | $15.03 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $14.50 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.57 | 2023 | Flumist Quadrivalent |
| Aytu Biopharma, INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.